SCHEMBL5146346

SCHEMBL5146346

CCOC(=O)[C@H](Cc1ccc(N)cn1)NC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.45
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
SCN9A Q15858 1/20 0.42
TACR1 P25103 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
KLK5 Q9Y337 1/20 0.39
CTSS P25774 4/20 0.38
CTSK P43235 3/20 0.38
PPID Q08752 1/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16489174 0.91 KLK5 (0.47) TACR1KLK5CTSSCTSKCTSL
SCHEMBL5262904 0.87 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19HTTALDH1A1
SCHEMBL2985149 0.87 ITGB3 (0.48) CTSSCTSKCTSLCTSBITGB3
SCHEMBL27589044 0.87 ITGB3 (0.48) CTSSCTSKCTSLCTSBITGB3
SCHEMBL5147742 0.83 PPARG (0.45) CYP1A2CYP2C9CYP2C19HTTALDH1A1
SCHEMBL1620166 0.82 CTSS (0.50) CYP1A2CYP2C9CYP2C19HTTALDH1A1
SCHEMBL2982541 0.82 CTSS (0.50) CYP1A2CYP2C9CYP2C19HTTALDH1A1
SCHEMBL13913373 0.82 CTSS (0.50) CYP1A2CYP2C9CYP2C19HTTALDH1A1
SCHEMBL16645014 0.80 KLK5 (0.45) ALDH1A1MAPTTACR1KLK5CTSS
SCHEMBL3722082 0.79 ACE (0.40) CYP1A2CYP2C9CYP2C19HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders UCB PHARMA S.A. (BE) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders ITGB2, VCAM1, ITGB1 CYP1A2 1449/4885CYP2C9 3265/4885CYP2C19 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.